Literature DB >> 3011693

Hospital experience with varicella-zoster virus.

K Krasinski, R S Holzman, R LaCouture, A Florman.   

Abstract

Varicella-zoster virus (VZV), one of the most common highly communicable agents of disease, stimulates aggressive infection control measures. In a 1-year period, at one hospital, at least 93 inpatients (82 adult patients, 11 pediatric patients) and 2 hospital staff with active varicella-zoster infections served as potential sources of nosocomial infection. Six incidents of exposure to the virus that occurred without the protection of standard infection control precautions were investigated by the infection control surveillance team. One hundred fifty-six patients and 353 hospital staff were exposed. Fifty-one patients had no history of varicella-zoster infection, but only five were susceptible by serologic testing. One hundred one staff members had no history of varicella-zoster, but only 11 were susceptible by serologic testing. These exposures resulted in three secondary varicella-zoster infections, six courses of varicella-zoster immune globulin prophylaxis and furlough of 13 staff members. Epidemiologic investigation consumed approximately 356 hours of staff time, and management of exposed persons cost approximately $41,500. Prospective knowledge of the immune status of health care workers would vastly decrease the time and effort required to control hospital VZV exposures.

Entities:  

Mesh:

Year:  1986        PMID: 3011693     DOI: 10.1017/s019594170006433x

Source DB:  PubMed          Journal:  Infect Control        ISSN: 0195-9417


  9 in total

1.  Varicella reinfection in a seropositive physician following occupational exposure to localized zoster.

Authors:  Jennifer A Johnson; Karen C Bloch; Bich N Dang
Journal:  Clin Infect Dis       Date:  2011-01-27       Impact factor: 9.079

Review 2.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

3.  An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92.

Authors:  T G Wreghitt; J Whipp; C Redpath; W Hollingworth
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

4.  Nosocomial varicella: worth preventing, but how?

Authors:  S R Preblud
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

5.  Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to-membrane-antigen test.

Authors:  P Larussa; S Steinberg; E Waithe; B Hanna; R Holzman
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

6.  Clinical benefits of routine varicella vaccination for adults.

Authors:  Cinzia Germinario; Maria Serena Gallone; Maria Giovanna Cappelli; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Impact and costs of varicella prevention in a university hospital.

Authors:  D J Weber; W A Rutala; C Parham
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

8.  Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient.

Authors:  Paul Bernstein; Yoko Furuya; Sharon Steinberg; Brian Scully; Philip Larussa; Anne A Gershon
Journal:  Am J Infect Control       Date:  2011-01-26       Impact factor: 2.918

9.  Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.

Authors:  A Sauerbrei; P Wutzler
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.